Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.79 USD | +2.29% | +7.19% | -32.96% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 2.36M |
---|---|---|---|---|---|
Net income 2024 * | -23M | Net income 2025 * | -26M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.13
x | P/E ratio 2025 * |
-0.07
x | Employees | 12 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.68% |
Latest transcript on Cyclacel Pharmaceuticals, Inc.
1 day | +2.29% | ||
1 week | +7.19% | ||
Current month | -15.16% | ||
1 month | -18.19% | ||
3 months | -17.13% | ||
6 months | -80.78% | ||
Current year | -32.96% |
Managers | Title | Age | Since |
---|---|---|---|
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 97-07-31 |
Paul McBarron
DFI | Director of Finance/CFO | 63 | 01-12-31 |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 20-12-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 83 | 06-02-28 | |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 20-12-16 |
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 97-07-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 1.79 | +2.29% | 28,374 |
24-04-22 | 1.75 | -1.69% | 25,527 |
24-04-19 | 1.78 | -3.78% | 10,391 |
24-04-18 | 1.85 | -5.61% | 37,911 |
24-04-17 | 1.96 | +17.37% | 115,080 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.96% | 2.36M | |
-0.49% | 105B | |
+3.31% | 97.5B | |
+1.66% | 22.19B | |
-16.16% | 21.33B | |
-6.82% | 18.68B | |
-41.41% | 16.6B | |
-22.87% | 14.52B | |
+6.32% | 14.09B | |
+21.46% | 10.99B |
- Stock Market
- Equities
- CYCC Stock